Tislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ Adenocarcinoma
Status:
Not yet recruiting
Trial end date:
2027-08-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy of Tislelizumab in the neoadjuvant
(prior to surgery) or adjuvant (after surgery) treatment of previously untreated adults with
gastric and gastroesophageal junction (GEJ) adenocarcinoma.
The primary study hypotheses are that:
Neoadjuvant and adjuvant Tislelizumab plus chemoradiotherapy, followed by adjuvant
Tislelizumab and chemotherapy is superior to neoadjuvant chemoradiotherapy or chemotherapy,
followed by adjuvant chemotherapy in terms of rate of Pathological Complete Response (pathCR)
at the time of surgery.
Phase:
Phase 2
Details
Lead Sponsor:
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School